Angiotech Pharmaceuticals ANPI
-
Athersys Shares Poised To Move Higher
… all the rights to its Multi-Stem Cardiovascular Cell Therapy Program from its collaborator and partner, Angiotech Pharmaceuticals , Inc. In an example of one man’s pain is another man’s gain, the recent bankruptcy restructuring of …
-
Athersys Announces Partnership Changes, New Financing Deal
… sales). Athersys also announced that it has terminated its cardiovascular-related collaboration with Angiotech Pharmaceuticals for MultiStem. Although a partner passing on rights to a drug would usually raise our eyebrows, we think …
-
Co-CIO Interview: Whitney George on Japan, Energy and Technology
With revenue streaming in from Boston Scientific's BSX Taxus stent sales, Angiotech ANPI is making considerable progress toward profitability. We still expect Angiotech to move into the black next year. Last spring …
-
UPDATE 1-Angiotech's creditors approve restructuring plan
April 5 (Reuters) - Canada's Angiotech Pharmaceuticals Inc said its creditors had approved a restructuring plan to cut $250 million of its debt.
-
A warning to investors in single-product companies – the Toronto Stock Exchange is delisting shares of Angiotech Pharmaceuticals ( ANPI .PK) as that company goes through bankruptcy proceedings. ANPI ...
… product companies – the Toronto Stock Exchange is delisting shares of Angiotech Pharmaceuticals ( ANPI .PK ) as that company goes through bankruptcy proceedings. ANPI had a moment of glory as the licensor of technology critical to Boston …
-
UPDATE 1- Angiotech Pharmaceuticals to file for bankruptcy
* Deal supported by majority of subordinated noteholders
-
Angiotech Pharmaceuticals Inc. ANPI
I took a beating with this stock. We still haven't found the bottom? I own it in an IRA and down $11,000. It is not a big position but still it HURTS. Any comments or advise is appreciated.
-
ATHX Reports Promising Phase I Data
Athersys ATHX , along with partner Angiotech Pharmaceuticals ANPI , announced positive results from a Phase I study of its MultiStem product in heart attack patients . While these favorable results …
-
New Morningstar Analyst Report - Angiotech Pharmaceuticals , Inc.
Switching costs for drug-eluting stents are low for end users, which could prove extremely detrimental to Angiotech if another crisis emerges around its paclitaxel-based platform.Angiotech's new products may not succeed for many reasons, including regulatory rulings or delays, tepid demand from
-
New Morningstar Analyst Report - Angiotech Pharmaceuticals , Inc.
While Angiotech looks out of immediate danger, long-term refinancing risk still looms large.